The Company expects full year generally accepted accounting principles operating expenses to be between $150 million and $160 million as compared to the previous guidance range of $135 million to $145 million. The increase is driven by additional operating expenses related to the integration of Clade Therapeutics, as well as the Company’s planned expanded clinical development of CNTY-101 into additional autoimmune disease indications. The Company is currently in the process of completing its accounting analysis of the acquisition of Clade. The revised guidance does not include any potential non-cash charges related to the acquisition. The Company estimates its cash, cash equivalents, and investments will support operations into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics price target lowered to $9 from $10 at Piper Sandler
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Questions or Comments about the article? Write to editor@tipranks.com